Literature DB >> 33512430

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.

Zemin Ren1,2, Marcel Spaargaren1,2, Steven T Pals1,2.   

Abstract

Plasma cells no longer express a B-cell antigen receptor and are hence deprived of signals crucial for survival throughout B-cell development. Instead, normal plasma cells, as well as their malignant myeloma counterparts, heavily rely on communication with the bone marrow (BM) microenvironment for survival. The plasma cell heparan sulfate proteoglycan (HSPG) syndecan-1 (CD138) and HSPGs in the BM microenvironment act as master regulators of this communication by co-opting specific growth and survival factors from the BM niche. This designates syndecan-1/HSPGs and their synthesis machinery as potential treatment targets in multiple myeloma.
© 2021 by The American Society of Hematology.

Entities:  

Year:  2021        PMID: 33512430     DOI: 10.1182/blood.2020008188

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

Review 1.  Role of extracellular matrix proteoglycans in immune cell recruitment.

Authors:  Anna L Gray; Nabina Pun; Amanda J L Ridley; Douglas P Dyer
Journal:  Int J Exp Pathol       Date:  2022-01-25       Impact factor: 2.793

2.  Biomarker Value of miR-221 and miR-222 as Potential Substrates in the Differential Diagnosis of Papillary Thyroid Cancer Based on Data Synthesis and Bioinformatics Approach.

Authors:  Shang Cai; Jiayan Ma; Yong Wang; Yuxing Cai; Liwei Xie; Xiangying Chen; Yingying Yang; Qiliang Peng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-07       Impact factor: 5.555

Review 3.  Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.

Authors:  Eyal Lebel; Boaz Nachmias; Marjorie Pick; Noa Gross Even-Zohar; Moshe E Gatt
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.